Many thanks to Vumedi, which sends out high quality neurosurgical video presentations, and who asked me to speak on Brain Tumors: The Year in Review. It’s 24 minutes, everyone is welcome to take a look! urldefense.com/v3/__https://…$
It is an honor to be an invited speaker (4 talks) at the Brazilian Congress of. Neurosurgery. There are many attendees (from Brazil and abroad) at this high energy event!
Yes that’s me speaking in front of the PowerPoint…
Michael Schulder retweeted
Please join us in congratulating the 2025-2026 @NeurosurgeryCNS Resident Fellow @dgolubMD and Deputy Resident Fellow Christopher Carr! We are excited to see what these two accomplish! Read more: bit.ly/4jfFVBB
#residentfellows #CNSJournal
Michael Schulder retweeted
ישראל - מנאום הצ׳חצ׳חים לנאום הכפכפים.
הקרדיט ל
@MichaelSchulder
I was pleased to give an invited keynote address at the annual meeting of the Israeli Neurosurgical Society today!
Topic: controversies in SRS for patients with brain metastases
Michael Schulder retweeted
Strong showing this year at #AANS2025 in #Boston with the whole @NorthwellNsurg @LenoxNeurosurg team! Great to have the whole team together with some of our recent alumni! 🧠
#Neurosurgery #Legacy @DanielSciubba @mschulder @drdavidlanger @ZuckerSoM @AANSNeuro
Michael Schulder retweeted
WELCOME TO OUR NEW NEUROSURGERY RESIDENTS!
Northwell Neurosurgery is SO excited to have you 🔥🧠
@JoshuaMcBriar @HDonaldson21 and Isabella Pecorari!
@NorthwellNsurg @LenoxNeurosurg @ZuckerSoM @CNSResidents @mschulder @DanielSciubba
#Match2025 #Neurosurgery #DREAMSCOMETRUE
Coronal images showing distribution of rhenium-186 completely covering the tumor in our patient with recurrent glioblastoma, whom we are treating as part of the Plus Therapeutics ReSPECT-GBM trial:
Michael Schulder retweeted
Honor to celebrate with an absolute legend at #SNO2024. Liz Pluhar from the @UMNews Brain Tumor Center has contributed more to understanding GBM than almost anyone I know. And has done it with such grace. #GOAT #canineglioma #BrainTumor
Presenting Alpheus CV101 results at #SNO2024. This was a phase 1 trial proving safety and also showing prolonged survival in people with recurrent high grade glioma!
Michael Schulder retweeted
Quick stop back in Houston 🚀 for #SNO2024 with out-of-this-world science and great discussions on IDH inhibitors and LGG management! @mschulder @dgolubMD @AnujGoenkaMD @NorthwellNsurg @ZuckerSoM @NeuroOnc
Northwell Neuroscience Brain Tumor Center. Rockin’ it at Society for Neurooncology 2024! #SNO2024 #NorthwellNeurosurgery #NorthwellHealth
Michael Schulder retweeted
Going to #SNO2024 in Houston? Come hear our exciting Phase 1/2 #FIH results for #BrainCancerTreatment and learn about our proprietary #sonodynamictherapy (SDT) solution for #glioblastoma treatment.
#CancerResearch #BrainCancer #NeuroOncology #BrainTumor #GlioblastomaResearch























